

# Indonesia

## Tuberculosis profile

Population 2017

264 million

Estimates of TB burden*, 2017	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	110 (100–110)	40 (38–43)
Mortality (HIV+TB only)	9.4 (5–15)	3.6 (1.9–5.8)
Incidence (includes HIV+TB)	842 (767–919)	319 (291–348)
Incidence (HIV+TB only)	36 (20–57)	14 (7.7–21)
Incidence (MDR/RR-TB)**	23 (16–31)	8.8 (6.2–12)

Estimated TB incidence by age and sex (thousands)*, 2017			
	0-14 years	> 14 years	Total
Females	23 (23–23)	326 (308–345)	349 (329–370)
Males	26 (26–27)	466 (435–497)	492 (458–526)
Total	49 (48–50)	792 (723–862)	842 (767–919)

TB case notifications, 2017	
Total cases notified	446 732
Total new and relapse	442 172
- % tested with rapid diagnostics at time of diagnosis	2%
- % with known HIV status	29%
- % pulmonary	90%
- % bacteriologically confirmed among pulmonary	54%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2017	53% (48–58)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2017	0.14 (0.12–0.15)

TB/HIV care in new and relapse TB patients, 2017		
	Number	(%)
Patients with known HIV-status who are HIV-positive	7 729	6%
- on antiretroviral therapy	2 244	29%

Drug-resistant TB care, 2017			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			12 000 (8 600–15 000)
Estimated % of TB cases with MDR/RR-TB	2.4% (1.8–3.3)	13% (9–18)	
% notified tested for rifampicin resistance	16%	223%	112 743
MDR/RR-TB cases tested for resistance to second-line drugs			1 813
Laboratory-confirmed cases		MDR/RR-TB: 5 070, XDR-TB: 51	
Patients started on treatment ****		MDR/RR-TB: 3 042, XDR-TB: 50	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2016	86%	364 671
Previously treated cases, excluding relapse, registered in 2016	71%	2 002
HIV-positive TB cases registered in 2016	64%	4 470
MDR/RR-TB cases started on second-line treatment in 2015	47%	1 565
XDR-TB cases started on second-line treatment in 2015	28%	32

TB preventive treatment, 2017	
% of HIV-positive people (newly enrolled in care) on preventive treatment	16%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	8.5% (7.8–9.3)

TB financing, 2018	
National TB budget (US\$ millions)	294
Funding source: 34% domestic, 16% international, 49% unfunded	


\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history


\*\*\*\* Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2017




■ Females ■ Males □ Incidence

Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



■ Unfunded  
■ Funded internationally  
■ Funded domestically